BC1-06 A double-blind, randomized, multiple dose, phase III, multicenter study of Alpharadin TM in the treatment of patients with hormone refractory prostate cancer with skeletal metastases
Laufzeit: 01.01.2009 - 31.12.2013
Kurzfassung
BC1-06 A double-blind, randomized, multiple dose, phase III, multicenter study of Alpharadin TM in the treatment of patients with hormone refractory prostate cancer with skeletal metastases
Beteiligte Einrichtungen
